Prostate Cancer
Prostate cancer incidence continues to rise by about 1% per year in the United States, with 192,000 new cases diagnosed in 2009. As increasing numbers of men follow recommendations to undergo PSA testing and digital rectal examination, the chances of detecting cancer still confined to the prostate—with optimal chances for a cure—also increase. How can clinicians help each patient make the best decisions regarding screening, biopsy, and (when required) treatment for the cancer that is second most common among US men?
58. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12): 1250-1261.
59. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11): 2388-2399.
60. Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease–induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866-873.
61. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000; 283(3):354-360.
62. Harden J, Northouse L, Cimprich B, et al. The influence of developmental life stage in quality of life in survivors of prostate cancer and their partners. J Cancer Surviv. 2008;2(2):84-94.
63. Potosky A, Legler J, Albertsen P, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92 (19):1582-1592.
64. Tsivian M, Polascik TJ. Focal cryotherapy for prostate cancer. Curr Urol Rep. 2010;11(3):
147-151.
65. Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(4):439-443.
66. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349 (3):215-224.
67. Kramer BS, Hagerty KL, Justman S, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009;27 (9):1502-1516.
68. Schellhammer PF, Higano C, Berger ER, et al; IMPACT Study Investigators. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen-independent prostatic adenocarcinoma (AIPC). Presented at: American Urological Association 104th Annual Scientific Meeting; April 28, 2009; Chicago, IL. Abstract 9.
69. Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010; 116(14):3389-3398.
70. Gutt R, Tonlaar N, Kunnavakkam R, et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010;28(16):2653-2659.
71. Kasperzyk JL, Fall K, Mucci LA, et al. One-carbon metabolism-related nutrients and prostate cancer survival. Am J Clin Nutr. 2009;90(3): 561-569.
72. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301(1): 52-62.
